Meeting Banner
Abstract #1110

First-in-human trial of Gd-based theranostic nanoparticles: MRI assessment of uptake and biodistribution in patients with multiple brain metastases

Sandrine Dufort1, Camille Verry2, Benjamin Lemasson3, Sylvie Grand2, Yannick Crémillieux4, François Lux5, Sébastien Mériaux6, Benoit Larrat6, Jacques Balosso2, Géraldine Le Duc1, Emmanuel L. Barbier3, and Olivier Tillement5

1NHTherAguix, Crolles, France, 2CHU Grenoble Alpes, Grenoble, France, 3GIN, Inserm, Université de Grenoble, Grenoble, France, 4Institut des Sciences Moléculaires, CNRS, Université de Bordeaux, Bordeaux, France, 5Institut Lumière Matière, CNRS, Université de Lyon, Villeurbanne, France, 6Neurospin, CEA, Gif-sur-Yvette, France

We report here the main MRI findings of a dose escalation phase 1 clinical trial with intravenous administration of theranostic AGuIX nanoparticles, conducted in 15 patients with brain metastases with the objective of evaluating the efficacy of the nanoparticles as contrast agent and radiosensitizer for brain metastases. The nanoparticles were found to enhance four different histological types of brain metastases up to one week after nanoparticle administration. Quantitative measurements of nanoparticle concentration in all types of brain metastases were obtained two hours after administration to patient - and incidentally two hours before the first session of whole brain radiotherapy.

This abstract and the presentation materials are available to members only; a login is required.

Join Here